Authors
Latest:
Jessica Robinson-Papp, MD: Medical Marijuana for Neurologic ConditionsThe professor of neurology at the Icahn School of Medicine at Mount Sinai spoke about what’s currently known about medical marijuana’s use, how CBD fits into the conversation, and what research still needs to be done.
Latest:
Amy B. Sullivan, PsyD: Screening MS Patients for ComorbiditiesThe director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of screening patients with MS for other conditions for which they are prevalently comorbid, such as depression or sleep disorders.
Latest:
Impressive Response Rates for Patients in Migraine Prevention Study: Peter J. Goadsby, MD, PhD, DScThe professor of neurology at King’s College, London, spoke about the phase 3 ELEVATE trial investigating atogepant for episodic migraine at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]
Latest:
Using Artificial Intelligence Applications in Neurology to the Field: Kathryn A. Davis, MD, MScThe associate professor of neurology and director of the Penn Epilepsy Center at the University of Pennsylvania talked about the potential of using artificial intelligence in the field of neurology as part of an upcoming session at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]
Latest:
CMSC Live: 2024 Annual Meeting Day 1Host Jeffrey Wilken, PhD, chats with Robert Naismith, MD; Jiwon Oh, MD, PhD; and Anthony Traboulsee, MD, about the first day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.
Latest:
Future Treatment of hATTR AmyloidosisAnalysis of current and newer therapies for the treatment of hereditary ATTR amyloidosis.
Latest:
Lutz Frolich, MD, PhD: Learning from Negative TrialsLutz Frölich, MD, PhD, spoke about the importance of continuing with research in light of negative trials in Alzheimer disease.
Latest:
Justifying Use of CGRP mAbs in Pediatric Patients With MigraineWhat happens to the approximately 24% of pediatric patients with migraine who do not respond to the preventive treatments recommended in the AAN guidelines?
Latest:
Jacqueline French, MD: Barriers to Identifying Nonmotor SeizuresThe director of Translational Research and Clinical Trials Epilepsy at NYU Grossman School of Medicine discussed the need to improve education about nonmotor seizures.
Latest:
Amit Rakhit, MD, MBA: Measuring Improvement in Fragile X Syndrome, Other Rare ConditionsThe chief medical officer and head of Research & Development at Ovid Therapeutics spoke about what prompted the development of this scale to measure improvement for patients with Fragile X syndrome, and possibly other conditions.
Latest:
Andre Machado, MD, PhD: Multidisciplinary Treatment in Movement DisordersThe Chairman of the Neurological Institute at Cleveland Clinic provided insight into the multidisciplinary decision-making process for patients with movement disorders at the center.
Latest:
Therapies for Children and Adults with Dravet SyndromeThe panelists discuss the possibility of treating Dravet syndrome in older children and adults and the effects if the therapies were effective.
Latest:
Steps in Translating Genetic Discoveries Into Effective Treatments for ALS: Matthew B. Harms, MDThe associate professor of neurology at Columbia University provided commentary on the rapid advancements in translating genetic research into ALS treatments and the challenges that remain. [WATCH TIME: 5 minutes]
Latest:
Future Treatment of hATTR AmyloidosisAnalysis of current and newer therapies for the treatment of hereditary ATTR amyloidosis.
Latest:
2020 Epilepsy Review: Much to Be Excited AboutDespite 2020 being a challenging year for those in medicine, the epilepsy therapeutic space featured a number of key steps forward.
Latest:
Hideki Garren, MD, PhD: Measuring MS Progression With Floodlight OpenThe smartphone application-led program, Floodlight Open, recently initiated in the US and Canada.
Latest:
Robert Califf, MD, Nominated by Biden Administration as Next FDA CommissionerHaving previously served as head of the organization during the Obama administration, Califf will replace current Acting Commissioner Janet Woodcock, MD.
Latest:
Davangere Devanand, MBBS, MD: Challenges in Symptom Management in Alzheimer DiseaseDavangere P. Devanand, MBBS, MD, discussed the possibility of neurologists prescribing low-dose lithium for patients with Alzheimer and symptoms of agitation.
Latest:
Aducanumab Reinvigorates the Fight Against Alzheimer DiseaseThe chief medical officer of ProMIS Neurosciences comments on how aducanumab will help propel innovation needed to drive the next generation of therapies for Alzheimer disease.
Latest:
Anli Liu, MD: Responsive Neurostimulation System for Cognition in EpilepsyLiu discussed this work and the findings of this proof-of-principle trial in memory in epilepsy.
Latest:
Novel and Emerging Targets in Multiple SclerosisExperts in neurology share their hopes for the future of multiple sclerosis treatment and discuss unmet needs and novel targets.
Latest:
Johan Verbraecken, MD, PhD: Challenges in Conducting Clinical Trials in OSAThe medical coordinator of the Multidisciplinary Sleep-Wake Disorders Center at Antwerp University Hospital spoke about how to address some of the issues faced in OSA treatment development.
Latest:
Zhibin Chen, PhD: Treatment Gap in Patients with Newly Diagnosed EpilepsyDespite accessibility to antiepileptic drugs in high-income settings, more than one-third of patients with newly diagnosed epilepsy were not treated or had delayed treatment.
Latest:
Shimrit Uliel-Sibony, MD: Can Patients Develop a CBD Tolerance?Uliel-Sibony discussed her and her colleagues' study of CBD, and its findings on when tolerance develops for which patient population.
Latest:
Trevor Resnick, MD: Treating Epilepsy By Blending Technology, Genetics, and PharmacologicsThe pediatric epileptologist at Nicklaus Children’s Hospital spoke about the future of epilepsy and shared which studies of the condition that he’s been keeping an eye on.
Latest:
Asher J. Albertson, MD, PhD: Getting Interventions to Stroke PatientsAlbertson discussed this facet of stroke care, and all the things being done outside just the clinic to help improve outcomes.
